Merkel Cell Carcinoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2021 Update

Pages: 1010 Published: December 30, 2021 Report Code: GMDGDHC13212IDB

Merkel cell carcinoma is a rare aggressive skin cancer that is at high risk of recurring and spreading (metastasizing) throughout the body. Risk factors for Merkel cell carcinoma include age, gender, light skin color, Ultraviolet exposure, and immune suppression. Symptom includes painless nodule on skin. It usually starts on areas of skin exposed to the sun (face, neck, arms, and legs). Treatment includes chemotherapy, radiation therapy, and surgery.

The Merkel Cell Carcinoma Drugs in Development market research report provides an overview of the Merkel Cell Carcinoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Merkel Cell Carcinoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Merkel Cell Carcinoma and features dormant and discontinued projects.

What are the targets of the Merkel Cell Carcinoma pipeline drugs market?

Some of the targets of the Merkel Cell Carcinoma pipeline drugs market are Programmed Cell Death Protein 1, Programmed Cell Death 1 Ligand 1, Cytotoxic T Lymphocyte Protein 4, E3 Ubiquitin Protein Ligase Mdm2, Interleukin 2 Receptor Subunit Beta, Mast/Stem Cell Growth Factor Receptor Kit, Vascular Endothelial Growth Factor Receptor 1, Vascular Endothelial Growth Factor Receptor 2, Vascular Endothelial Growth Factor Receptor 3, and Brachyury Protein.

Merkel Cell Carcinoma pipeline drugs market, by targets

Merkel Cell Carcinoma pipeline drugs market, by targets

For more target insights, download a free report sample

What are the mechanisms of action of the Merkel Cell Carcinoma pipeline drugs market?

Some of the mechanisms of action of the Merkel Cell Carcinoma pipeline drugs market are Programmed Cell Death Protein 1 Antagonist, Programmed Cell Death 1 Ligand 1 Inhibitor, Cytotoxic T Lymphocyte Protein 4 Antagonist, E3 Ubiquitin Protein Ligase Mdm2 Inhibitor, Interleukin 2 Receptor Subunit Beta Agonist, Mast/Stem Cell Growth Factor Receptor Kit Inhibitor, Vascular Endothelial Growth Factor Receptor 1 Inhibitor, Vascular Endothelial Growth Factor Receptor 2 Inhibitor, Vascular Endothelial Growth Factor Receptor 3 Inhibitor, and Cytotoxic To Cells Expressing Glypican 3.

Merkel Cell Carcinoma pipeline drugs market, by mechanisms of action

Merkel Cell Carcinoma pipeline drugs market, by mechanisms of action

For more mechanisms of action insights, download a free report sample

What are the routes of administration in the Merkel Cell Carcinoma pipeline drugs market?

Some of the routes of administration in the Merkel Cell Carcinoma pipeline drugs market are intravenous, intratumor, subcutaneous, oral, intralesional, parenteral, intraperitoneal, intravesical, intradermal, and intramuscular.

Merkel Cell Carcinoma pipeline drugs market, by routes of administration

Merkel Cell Carcinoma pipeline drugs market, by routes of administration

For more routes of administration insights, download a free report sample

What are the molecule types in the Merkel Cell Carcinoma pipeline drugs market?

The molecule types in the Merkel Cell Carcinoma pipeline drugs market are monoclonal antibody, small molecule, cell therapy, fusion protein, oligonucleotide, oncolytic virus, recombinant vector vaccine, DNA vaccine, gene-modified cell therapy, and recombinant protein.

Merkel Cell Carcinoma pipeline drugs market, by molecule types

Merkel Cell Carcinoma pipeline drugs market, by molecule types

For more molecule type insights, download a free report sample

Which are the key companies in the Merkel Cell Carcinoma pipeline drugs market?

Some of the key companies in the Merkel Cell Carcinoma pipeline drugs market are Bristol-Myers Squibb Co, Incyte Corp, Bavarian Nordic A/S, F. Hoffmann-La Roche Ltd, Fate Therapeutics Inc, ImmunityBio Inc, Merck & Co Inc, Nektar Therapeutics, Sotio AS, and 4SC AG.

Merkel Cell Carcinoma pipeline drugs market, by key companies

Merkel Cell Carcinoma pipeline drugs market, by key companies

To know more about key companies, download a free report sample

Market report scope

Targets Programmed Cell Death Protein 1, Programmed Cell Death 1 Ligand 1, Cytotoxic T Lymphocyte Protein 4, E3 Ubiquitin Protein Ligase Mdm2, Interleukin 2 Receptor Subunit Beta, Mast/Stem Cell Growth Factor Receptor Kit, Vascular Endothelial Growth Factor Receptor 1, Vascular Endothelial Growth Factor Receptor 2, Vascular Endothelial Growth Factor Receptor 3, and Brachyury Protein
Mechanisms of Action Programmed Cell Death Protein 1 Antagonist, Programmed Cell Death 1 Ligand 1 Inhibitor, Cytotoxic T Lymphocyte Protein 4 Antagonist, E3 Ubiquitin Protein Ligase Mdm2 Inhibitor, Interleukin 2 Receptor Subunit Beta Agonist, Mast/Stem Cell Growth Factor Receptor Kit Inhibitor, Vascular Endothelial Growth Factor Receptor 1 Inhibitor, Vascular Endothelial Growth Factor Receptor 2 Inhibitor, Vascular Endothelial Growth Factor Receptor 3 Inhibitor, and Cytotoxic To Cells Expressing Glypican 3
Routes of Administration Intravenous, Intratumor, Subcutaneous, Oral, Intralesional, Parenteral, Intraperitoneal, Intravesical, Intradermal, and Intramuscular
Molecule Types Monoclonal Antibody, Small Molecule, Cell Therapy, Fusion Protein, Oligonucleotide, Oncolytic Virus, Recombinant Vector Vaccine, DNA Vaccine, Gene-Modified Cell Therapy, and Recombinant Protein
Key Companies Bristol-Myers Squibb Co, Incyte Corp, Bavarian Nordic A/S, F. Hoffmann-La Roche Ltd, Fate Therapeutics Inc, ImmunityBio Inc, Merck & Co Inc, Nektar Therapeutics, Sotio AS, and 4SC AG

This report provides:

  • A snapshot of the global therapeutic landscape of Merkel Cell Carcinoma.
  • Reviews of pipeline therapeutics for Merkel Cell Carcinoma by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
  • Descriptive drug profiles for the pipeline products which include product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities.
  • Key players involved in Merkel Cell Carcinoma therapeutics and enlists all their major and minor projects.
  • Assessment of Merkel Cell Carcinoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA), and molecule type.
  • All the dormant and discontinued pipeline projects.
  • Reviews of the latest news related to pipeline therapeutics for Merkel Cell Carcinoma.

Reasons to Buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies.
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Identify and understand important and diverse types of therapeutics under development for Merkel Cell Carcinoma.
  • Identify potential new clients or partners in the target demographic.
  • Develop strategic initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics.
  • Devise corrective measures for pipeline projects by understanding Merkel Cell Carcinoma pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Key Players

4SC AG

Aileron Therapeutics Inc

Alphamab Oncology

Amgen Inc

Apcure SAS

Arcus Biosciences Inc

Bavarian Nordic A/S

BeiGene Ltd

Beijing Advaccine Biotechnology Company Ltd

BeyondSpring Inc

BioInvent International AB

Biosion Inc

bluebird bio Inc

Boston Pharmaceuticals Inc

Bristol-Myers Squibb Co

Checkmate Pharmaceuticals Inc

Checkpoint Therapeutics Inc

Codiak BioSciences Inc

CStone Pharmaceuticals Co Ltd

CytomX Therapeutics Inc

Eisai Co Ltd

Eli Lilly and Co

Exelixis Inc

Exicure Inc

F-star Therapeutics Inc

F. Hoffmann-La Roche Ltd

Fate Therapeutics Inc

Genexine Inc

Genocea Biosciences Inc

Harbin Gloria Pharmaceuticals Co Ltd

ImmunityBio Inc

Immunomic Therapeutics Inc

Incyte Corp

Kartos Therapeutics Inc

Lytix Biopharma AS

Medicenna Therapeutics Corp

Memgen Inc

Merck & Co Inc

Merck KGaA

Morphogenesis Inc

Nektar Therapeutics

NextCure Inc

Novartis AG

Ocellaris Pharma Inc

OncoC4 Inc

OncoSec Medical Inc

Oncovir Inc

Ono Pharmaceutical Co Ltd

PokeAcell

QBiotics Group Ltd

Rain Therapeutics Inc

Regeneron Pharmaceuticals Inc

Replimune Ltd

Seven and Eight Biopharmaceuticals Corp

Simcha Therapeutics Inc

Sotio AS

Tarveda Therapeutics Inc

Treadwell Therapeutics Inc

Xencor Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Merkel Cell Carcinoma – Overview

Merkel Cell Carcinoma – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Merkel Cell Carcinoma – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Merkel Cell Carcinoma – Companies Involved in Therapeutics Development

Merkel Cell Carcinoma – Drug Profiles

Merkel Cell Carcinoma – Dormant Projects

Merkel Cell Carcinoma – Discontinued Products

Merkel Cell Carcinoma – Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Merkel Cell Carcinoma, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Products under Development by Companies, 2021

Products under Development by Universities/Institutes, 2021

Number of Products by Stage and Target, 2021

Number of Products by Stage and Mechanism of Action, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Merkel Cell Carcinoma – Dormant Projects, 2021

Merkel Cell Carcinoma – Discontinued Products, 2021

List of Figures

List of Figures

Number of Products under Development for Merkel Cell Carcinoma, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Number of Products by Top 10 Targets, 2021

Number of Products by Stage and Top 10 Targets, 2021

Number of Products by Top 10 Mechanism of Actions, 2021

Number of Products by Stage and Top 10 Mechanism of Actions, 2021

Number of Products by Top 10 Routes of Administration, 2021

Number of Products by Stage and Top 10 Routes of Administration, 2021

Number of Products by Top 10 Molecule Types, 2021

Number of Products by Stage and Top 10 Molecule Types, 2021

Frequently Asked Questions

Enquire Before Buying
$2000

Can be used by individual purchaser only

$6000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.